Literature DB >> 3754573

Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer.

M T Knobf.   

Abstract

The incidence of physical toxicity and psychosocial effects associated with adjuvant chemotherapy for stage II breast cancer have been reported in previous studies. The purpose of this exploratory study was to quantify the degree of physical and psychologic distress experienced by patients and identify life-style changes. A semistructured interview was conducted with 78 subjects to elicit demographic data, distress, and life-style changes using the Symptoms Distress Scale (SDS), the Psychiatric Status Schedule (PSS), and questions and scales developed by the investigator. All subjects received adjuvant chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil with or without vincristine and prednisone) following primary treatment for breast carcinoma. Fifty subjects were currently on therapy and 28 had completed treatment. Fatigue was the most distressful physical symptom. Although physical distress was rated higher by subjects receiving treatment, generally all rating scores indicated only mild symptom distress. Subjects perceived more distress for the psychologic and emotional response to disease and treatment, and this persisted for women who completed therapy. Changes in role performance and daily activity were minimal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754573     DOI: 10.1200/JCO.1986.4.5.678

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  Further validation of the multidimensional fatigue symptom inventory-short form.

Authors:  Kevin D Stein; Paul B Jacobsen; Chris M Blanchard; Christina Thors
Journal:  J Pain Symptom Manage       Date:  2004-01       Impact factor: 3.612

2.  Cancer-related fatigue and associated disability in post-treatment cancer survivors.

Authors:  Jennifer M Jones; Karin Olson; Pamela Catton; Charles N Catton; Neil E Fleshner; Monika K Krzyzanowska; David R McCready; Rebecca K S Wong; Haiyan Jiang; Doris Howell
Journal:  J Cancer Surviv       Date:  2015-04-16       Impact factor: 4.442

Review 3.  The relationship between fatigue and sleep in cancer patients: a review.

Authors:  S Ancoli-Israel; P J Moore; V Jones
Journal:  Eur J Cancer Care (Engl)       Date:  2001-12       Impact factor: 2.520

4.  Psychosocial sequelae of breast cancer and its treatment.

Authors:  A Moyer; P Salovey
Journal:  Ann Behav Med       Date:  1996-06

5.  Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer.

Authors:  Sonia Ancoli-Israel; Lianqi Liu; Matthew R Marler; Barbara A Parker; Vicky Jones; Georgia Robins Sadler; Joel Dimsdale; Mairav Cohen-Zion; Lavinia Fiorentino
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

6.  Psychosocial and Physical Effects of Adjuvant Chemotherapy: Survey of younger women with breast cancer.

Authors:  T G Hislop; J M Elwood; N Waxler-Morrison; J Ragaz; D H Skippen; I D Turner
Journal:  Can Fam Physician       Date:  1991-05       Impact factor: 3.275

7.  A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer.

Authors:  Helen G Mar Fan; Mark Clemons; Wei Xu; Irene Chemerynsky; Henriette Breunis; Sharon Braganza; Ian F Tannock
Journal:  Support Care Cancer       Date:  2007-10-31       Impact factor: 3.603

8.  Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

Authors:  D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman
Journal:  Qual Life Res       Date:  1998-05       Impact factor: 4.147

9.  Predicting recurrence in axillary-node negative breast cancer patients.

Authors:  D Rosner; W W Lane
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Rehabilitation needs and breast cancer: the first month after primary therapy.

Authors:  P A Ganz; C C Schag; M L Polinsky; R L Heinrich; V F Flack
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.